In particular, one retrospective cohort study reported that Dupilumab, a monoclonal antibody inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, alleviated ETD at a similar magnitude as ESS in Th2-driven CRS [32]. This evidence concerns the gene IL13 and congenital rubella syndrome.